0.645
-0.61 (-48.40%)
| Previous Close | 1.25 |
| Volume | 587,891 |
| Price / Sales | 0.390 |
| 52 Weeks Range |
| Profit Margin | -146.93% |
| Operating Margin (TTM) | -557.51% |
| Diluted EPS (TTM) | -15.27 |
| Quarterly Revenue Growth (YOY) | -54.00% |
| Current Ratio (MRQ) | 0.100 |
| Operating Cash Flow (TTM) | 15.96 M |
| Levered Free Cash Flow (TTM) | 42.76 M |
| Return on Assets (TTM) | -69.26% |
AIStockmoo Score
| Value 30% | -2.3 |
| From our AI Insight report's view of expected return against risk. info | NA |
| Relative Valuation info | NA |
| Implied Growth info | NA |
| Valuation History info | NA |
| Weak profitability. Thin short-term liquidity. Positive cash flow. info | |
| Return on Capital info | NA |
| Timing 30% | -4.7 |
| From our AI technical analysis of the chart. info | NA |
| Downtrend over the past year. Far below its 52-week high. info | |
| Candle Patterns info | NA |
| Trend for Your Holding Period info | NA |
| Sentiment 20% | 0.0 |
| No recent price targets, so based on how targets have been revised. info | |
| News Mood info | NA |
| Smart Money 20% | 2.3 |
| Insider Activity info | NA |
| Institutions net +2.26% of shares in their latest 13F filings: 26 holders increased, 28 decreased (quarter to 30 Sep 2026). info | |
| Short interest -16.8% from 31 Aug to 30 Oct 2026, 3.4 days to cover (FINRA). info | |
| Market and sector conditions are neutral. | |
| Market environment cautious. info | |
| Sector outperforming the market. | |
| The pillars agree, so the score is strengthened. | |
| Not in score | |
| Price is low against its 52-week average. Down over 5 years. info | |
| Trend down on all three terms. Short-term momentum falling. info | |
| No clear signal from support and resistance. info | |
| Final Score | -1.72 |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - General (US) | Mixed | Bullish |
| Drug Manufacturers - General (Global) | Mixed | Bullish | |
| Stock | Scilex Holding Company | Mixed | Mixed |
Similar Stocks
| Stock | Market Cap | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| SCLX | - | - | - | - |
| SNY | - | 5.10% | - | 1.40 |
| AMGN | - | 2.17% | - | 17.55 |
| GILD | - | 1.94% | - | 16.00 |
| GRFS | - | 1.08% | - | 0.900 |
| BIIB | - | - | - | 1.98 |
Select this tab to load the latest available analysis.
|
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Investment Style | Small Value |
| % Held by Insiders | 21.58% |
| % Held by Institutions | 18.55% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Ashton Thomas Private Wealth, Llc | 30 Sep 2026 | 23,832 |
No data within this time range.
No data within this time range.
Institutions
Institutional ownership: 13.03%
| Positions | Holders | Shares |
|---|---|---|
| Increased | 26 | 153,919 |
| Decreased | 28 | 32,382 |
| New | 17 | 61,923 |
| Sold out | 14 | 2,669 |
SEC 13F filings via Nasdaq, latest filings up to 30 Sep 2026. Filings arrive up to 45 days after each quarter.
Short Interest
| Settlement | Shares | Days to cover |
|---|---|---|
| 30 Oct 2026 | 132,205 | 3.4 |
| 15 Oct 2026 | 148,382 | 2.6 |
| 30 Sep 2026 | 171,151 | 5.8 |
| 15 Sep 2026 | 176,711 | 5.9 |
| 31 Aug 2026 | 158,922 | 3.1 |
| 14 Aug 2026 | 152,585 | 4.0 |
FINRA short interest via Nasdaq, reported twice a month.
| Date | Type | Details |
|---|---|---|
| 28 Oct 2026 | Yahoo Finance |
Datavault AI Stock Jumps 31% Even as Its Bitcoin Sits Stuck at Biconomy
Its restatement takes every reported bitcoin off the books, including 837 BTC Scilex agreed to buy in June. No definitive deal has been disclosed. |
| 28 Oct 2026 | Yahoo Finance |
Bitcoin Treasury Datavault AI Says It Can’t Access Its BTC, Stock Tanks
Datavault AI says it has been unable to withdraw its Bitcoin from Biconomy since June and will restate four financial reports tied to a $150 million Scilex deal. |
| 28 Oct 2026 | Yahoo Finance |
$150 Million Bitcoin Controversy Crashes a Nasdaq Stock
A $150 million Bitcoin deal left Datavault AI unable to reach its coins. Its stock lost half its value. What happened? |
| 28 Oct 2026 | Yahoo Finance |
Datavault AI Says It Can’t Access Its Bitcoin Holdings
Crypto treasury firm Datavault AI (NASDAQ: $DVLT) says it is unable to access a large portion of its Bitcoin (CRYPT… |
| 20 Aug 2026 | Yahoo Finance |
Federal Court Grants Motion to Stay Proceedings in Scilex v. Wade et al.
The St. James Bank & Trust Company Ltd. ("St. James"), Omega & Corinth Group Ltd. and Marc Wade today announced that the U.S. District Court has granted their motion to compel arbitration and stay all court proceedings in California brought by Scilex Holding Company ("Scilex").. |
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |